Effectively nursing patients receiving aromatase inhibitor therapy
Autor: | Yvonne Wengström |
---|---|
Rok vydání: | 2007 |
Předmět: |
Oncology
medicine.medical_specialty Antineoplastic Agents Hormonal medicine.drug_class Anastrozole Breast Neoplasms Comorbidity Weight Gain Breast cancer Patient Education as Topic Internal medicine Antineoplastic Combined Chemotherapy Protocols Nitriles medicine Adjuvant therapy Humans Aromatase Adverse effect Lubricants Aromatase inhibitor biology business.industry Aromatase Inhibitors General Medicine Triazoles medicine.disease Arthralgia Menopause Tamoxifen Cardiovascular Diseases Hot Flashes Vagina biology.protein Quality of Life Surgery Female Atrophy Neoplasm Recurrence Local business medicine.drug |
Zdroj: | Breast (Edinburgh, Scotland). 17(3) |
ISSN: | 0960-9776 |
Popis: | Inhibiting estrogen production is a common means of preventing breast cancer recurrence. The aromatase inhibitors (AIs) are becoming the preferred treatment over tamoxifen as adjuvant therapy for postmenopausal women with hormone-sensitive early breast cancer. Like all adjuvant therapies, AIs have adverse events (AEs) associated with their use, many of which resemble symptoms common to menopause. Because of the greater efficacy of AIs in preventing breast cancer recurrence over tamoxifen, these AEs may be considered tolerable by many patients and often can be effectively managed and/or prevented. Educating patients about anticipated AEs may help them understand, accept, and cope with these AEs. This article reviews the AEs associated with different adjuvant AI treatments and highlights some strategies to manage them effectively. It also highlights the importance of patient education regarding AI therapy and involvement in treatment decisions, which may lead to better long-term adherence and ultimately to better outcomes. |
Databáze: | OpenAIRE |
Externí odkaz: |